Health policy analysis
in full colour

Our research methods help policy makers make fairer decisions with better health outcomes.

The problem. Existing analyses focus on a mythical average citizen.

The solution. We develop ways of analysing who gains and loses from health policies.

Find out more

Monitoring Fairness in the NHS

Latest tweets

Welcome to CHE’s second newsletter of 2019, Issue 35

New blog post- - on the @CHEyork Hospital Episode Statistics (HES) course I attended last week. Have a read if you want to know more about it and how it got me thinking about the gap for this type of course in Scotland... #admindata #datalinkage #training

Load More...

New resources


Publication details

Journal Psychiatric services (Washington, D.C.)
Date Accepted/In press - 21 Mar 2019
Date E-pub ahead of print (current) - 21 May 2019
Number of pages 7
Early online date 21/05/19
Original language English


OBJECTIVE: Although U.K. and international guidelines recommend monotherapy, antipsychotic polypharmacy among patients with serious mental illness is common in clinical practice. However, empirical evidence on its effectiveness is scarce. Therefore, the authors estimated the effectiveness of antipsychotic polypharmacy relative to monotherapy in terms of health care utilization and mortality.

METHODS: Primary care data from Clinical Practice Research Datalink, hospital data from Hospital Episode Statistics, and mortality data from the Office of National Statistics were linked to compile a cohort of patients with serious mental illness in England from 2000 to 2014. The antipsychotic prescribing profile of 17,255 adults who had at least one antipsychotic drug record during the period of observation was constructed from primary care medication records. Survival analysis models were estimated to identify the effect of antipsychotic polypharmacy on the time to first occurrence of each of three outcomes: unplanned hospital admissions (all cause), emergency department (ED) visits, and mortality.

RESULTS: Relative to monotherapy, antipsychotic polypharmacy was not associated with increased risk of unplanned hospital admission (hazard ratio [HR]=1.14; 95% confidence interval [CI]=0.98-1.32), ED visit (HR=0.95; 95% CI=0.80-1.14), or death (HR=1.02; 95% CI=0.76-1.37). Relative to not receiving antipsychotic medication, monotherapy was associated with a reduced hazard of unplanned admissions to the hospital and ED visits, but it had no effect on mortality.

CONCLUSIONS: The study results support current guidelines for antipsychotic monotherapy in routine clinical practice. However, they also suggest that when clinicians have deemed antipsychotic polypharmacy necessary, health care utilization and mortality are not affected.

Bibliographical note

This is an author-produced version of the published paper. Uploaded in accordance with the publisher’s self-archiving policy. Further copying may not be permitted; contact the publisher for details.


EQUIPOL is supported by the University of York, the Wellcome Trust (Grant No. 205427/Z/16/Z) and the NIHR (SRF-2013-06-015).

Image Image Image